Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 610

[378] Sershen SR, Westcott SL, Halas NJ, West NJ. Temperature sensitive polymer-nanoshell
composites for photothermally modulated drug delivery. J Biomed Mater Res 2000;51:
293-8.
[379] Heller J. Modulated release from drug delivery devices. Crit Rev Ther Drug Carrier
Syst 1993;10:253-305.
[380] Banerjee PS, Hosny EA, Robinson JR. Parenteral delivery of peptide and protein drugs.
In: Lee VHL, editor. Peptide and protein drug delivery. New York, NY: Marcel Dekker;
1991. p. 487-543.
[381] Leichter SB, Schreiner ME, Reynolds LR, Bolick T. Long-term follow-up of diabetic
patients using insulin infusion pumps: considerations for future clinical application.
Arch Intern Med 1985;145:1409-12.
[382] Autosyringe. National Public Web site on Assistive Technology. http:// atwiki.assis-
tivetech.net/index.php/AutoSyringe. Accessed May 2010.
[383] Leyendecker G, Wildt L, Hansmann M. Pregnancies following chronic intermittent (pul-
satile) administration of Gn-RH by means of a portable pump (“ZYKLOMAT”)—a new
approach to the treatment of infertility in hypothalamic amenorrhea. J Clin Endocrinol
Metab 1980;51:1214-16.
[384] Wright JC, Culwell J. Long term controlled release of therapeutic agents by the osmot-
ically driven Duros implant ® . In: Rathbone MJ, editor. Modified release drug delivery
technology. 1st ed., vol. 2 New York, NY: Marcel Dekker; 2003. p. 143-8.
[385] Lynch HJ, Rivest RW, Wurtman RJ. Artificial induction of melatonin rhythms by pro-
grammed microinfusion. Neuroendocrinology 1980;31:106-11.
[386] Fuertges A, Abuchowski A. The clinical efficacy of poly (ethylene glycol)-modified
proteins. J Control Release 1990;11:139-48.
[387] Harris JM. Introduction to biotechnical and biomedical applications of poly (ethylene
glycol). In: Harris JM, editor. Poly(ethylene glycol) chemistry: biotechnical and bio
medical applications. New York, NY: Plenum Press; 1992. p. 1-12.
[388] Pasut G, Veronese FM. Polymer-drug conjugation, recent achievements and general
strategies. Prog Polym Sci 2007;32:933-61.
[389] Huang S, Pooyan S, Wang J, Choudhury I, Leibowitz MJ, Stein S. A polyethylene gly-
col copolymer for carrying and releasing multiple copies of cysteine-containing pep-
tides. Bioconjug Chem 1998;9:612-17.
[390] Freitas Dda S, Abrahão-Neto J. Biochemical and biophysical characterization of lyso-
zyme modified by PEGylation. Int J Pharm 2010;392:111-17.
[391] Veronese FM, Caliceti P, Schiavon O. Branched and linear poly(ethylene glycol): influ-
ence of the polymer structure on enzymological, pharmacokinetic, and immunological
properties of protein conjugates. J Bioact Comp Polym 1997;12:196-207.
[392] Veronese FM, Harris JM. Introduction and overview of peptide and protein PEGylation.
Adv Drug Delivery Rev 2002;54:453-6.
[393] Jevševar S, Kunstelj M, Gaberc Porekar V. PEGylation of therapeutic proteins.
Biotechnol J 2010;5:113-28.
[394] Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate
novel therapeutics. J Pharm Sci 2008;97:4167-83.
[395] Katre NV. The conjugation of proteins with polyethylene glycol and other polymers—
altering properties of proteins to enhance their therapeutic potential. Adv Drug Del Rev
1993;10:91-114.
[396] Zhang M, Dou H, Yin L, Zhang Y, Zhu S, Yin C. Preparation and characterization of
monomethoxypoly (ethylene glycol)-insulin conjugates. Die Pharmazie 2009;64:
190-6.